You are here:Home-Community manager
Community manager

About Community manager

This author has not yet filled in any details.
So far Community manager has created 129 blog entries.

Drug Discovery Data Insights: Highly Accessible SAR Data is Transforming the Drug Discovery Informatics Landscape

On June 26th, 2018, Collaborative Drug Discovery (CDD) hosted a webinar where moderator Ashley Farley, Associate Officer of Knowledge & Research Services at the Bill & Melinda Gates Foundation (BMGF) discussed drug discovery data with Dr. Andrew Leach from ChEMBL and Dr. Evan Bolton from PubChem. The presenters discussed the emergence of freely available PubChem and ChEMBL resources for chemical and biological Structure-Activity-Relationship (SAR) data and their impact on the global drug discovery informatics landscape. The relationship between

Drug Discovery Data Insights: Highly Accessible SAR Data is Transforming the Drug Discovery Informatics Landscape2019-01-11T15:25:30+00:00

Alternatives to (classical) antibiotics: what will it take to convincingly develop a virulence inhibitor or similar indirect agent?

John H. Rex Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed

Alternatives to (classical) antibiotics: what will it take to convincingly develop a virulence inhibitor or similar indirect agent?2019-01-07T09:20:25+00:00

PK-PD in support of accelerated programmes: how much is enough?

William Hope Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed up

PK-PD in support of accelerated programmes: how much is enough?2019-01-07T09:20:41+00:00

US regulatory tools for expedited antibacterial development programmes

Sumathi Nambiar Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed up

US regulatory tools for expedited antibacterial development programmes2019-01-07T09:20:56+00:00

EU regulatory tools for expedited antibacterial development programmes

Marco Cavaleri Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed up

EU regulatory tools for expedited antibacterial development programmes2019-01-07T09:21:14+00:00

Decisions, Decisions: What Makes a Good Hit? A Good Lead? Why Do You Write a TPP? How Do You Write a TPP?

Antibiotic Bootcamps for Developers A collaborative project of CARB-Xed, GARDP, ASM, and ESCMID 5-8 September 2017, ASM-ESCMID Conference, Boston Moderator: Lynn Silver, LL Silver Consulting, LLC Discussants:  Lynn Silver, LL Silver Consulting, LLC Tom Dougherty, Harvard Medical School John Tomayko, Infectious Diseases Consultant Sherman T. Waddell, Prokaryotics, Inc. Date : September 5th, 2017

Decisions, Decisions: What Makes a Good Hit? A Good Lead? Why Do You Write a TPP? How Do You Write a TPP?2019-01-07T09:21:28+00:00

How Does a Molecule Become a Physical Medicine to be Given to a Human: The Importance of Chemistry, Manufacturing, and Controls

Antibiotic Bootcamps for Developers A collaborative project of CARB-Xed, GARDP, ASM, and ESCMID 5-8 September 2017, ASM-ESCMID Conference, Boston Moderator: Tim Keutzer, Spero Therapeutics Discussants: Tim Keutzer, Spero Therapeutics Evan Hecker, Spero Therapeutics Mike Young, Tedor Pharma Inc Andrew Barlow, Syner-G Pharma Consulting Date : September 5th, 2017

How Does a Molecule Become a Physical Medicine to be Given to a Human: The Importance of Chemistry, Manufacturing, and Controls2019-01-07T09:21:42+00:00

Clinical Microbiology for a Development Program

Antibiotic Bootcamps for Developers A collaborative project of CARB-Xed, GARDP, ASM, and ESCMID 5-8 September 2017, ASM-ESCMID Conference, Boston Moderator: Judith Steenbergen, Paratek Pharmaceuticals Discussants: Erika Matuschek, EUCAST: Investigational New Drug - Groundwork for in vitro antimicrobial susceptibility testing Kevin Krause, Achaogen: NDA Requirements: Surveillance, Clinical Trial Data, Breakpoints Robin Patel, Mayo Clinic: Making Antibacterial Susceptibility Available in Clinical Practice Roundtable: Pitfalls in Development Date : September 5th, 2017

Clinical Microbiology for a Development Program2019-01-07T09:21:54+00:00

Jesús Rodríguez-Baño

Jesús Rodríguez-Baño is Professor of Medicine at the University of Seville and Head of the Infectious Diseases division at Hospital Universitario Virgen Macarena in Seville, Spain. He is also Scientific Chair of the Spanish Network for Research in Infectious Diseases (REIPI), which is funded by Instituto de Salud Carlos III, and President-Elect of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Jesús is a medical doctor and specialist in internal medicine, who gained his PhD in medicine in

Jesús Rodríguez-Baño2020-01-13T13:10:06+00:00

Michael Barbachyn

Michael Barbachyn is the Brummel Chair and Professor of Organic Chemistry at Calvin College, Michigan, US, and an independent consultant at Barbachyn Consulting. Michael has over 27 years’ experience in medicinal chemistry as a research scientist following periods at Upjohn, Pharmacia & Upjohn, Bristol-Myers Squibb, Pharmacia, Pfizer and AstraZeneca, focused on anti-infectives. Michael also has 12 years’ pharmaceutical industry management experience as an associate director and director in antibacterial medicinal chemistry at Pharmacia and then Pfizer; and as an infection

Michael Barbachyn2020-01-21T08:28:39+00:00

Greg Basarab

Greg Basarab is Principal Research Officer and Associate Director at the University of Cape Town (UCT), Drug Discovery and Development Centre (H3D). He is Head of drug metabolism and pharmacokinetics (DMPK) and pharmacology groups located at Groote Schuur Hospital, Head of Institute of Infectious Diseases and Molecular Medicine, and Head of Medicinal Chemistry groups within the UCT Chemistry Department. He lectures at the UCT Medical School on Drug Disposition and Pharmacology. Greg worked in various aspects of antibacterial and antifungal

Greg Basarab2020-02-04T12:03:08+00:00

Alex van Belkum

Alex van Belkum is currently Scientific Director of Microbiology Research at bioMérieux, a diagnostics company based in the South of France. He is also a fellow of the American Academy of Microbiology. Alex is a microbiologist in the data analytics unit of bioMérieux with a prime interest in next generation sequencing, and the use of other data-rich technologies in clinical microbiology. His long career has been dedicated to the research of molecular epidemiology, molecular and culture-based diagnostics and antimicrobial resistance

Alex van Belkum2018-08-29T13:54:05+00:00

Julia Bielicki

Julia Bielicki is currently a consultant in Paediatric Infectious Diseases and Infection Prevention and Control at the University of Basel Children’s Hospital. She is also an active researcher with the Paediatric Pharmacology Division at the University of Basel Children’s Hospital and a Senior Lecturer with the Paediatric Infectious Diseases Research Group at St George’s University of London. Furthermore, Julia is involved in developing a national antimicrobial stewardship programme in Switzerland. Julia’s research focuses on observational and interventional studies that aim

Julia Bielicki2018-10-09T12:12:44+00:00

Helen W. Boucher

Helen Boucher is currently chief of the Division of Geographic Medicine and Infectious Diseases. She is also Director of the Tufts Center for Integrated Management of Antimicrobial Resistance (CIMAR), a collaborative, cross-disciplinary initiative between Tufts University and Tufts Medical Center. She is Director of TMC’s Heart Transplant and Ventricular Assist Device Infectious Diseases Program and Professor of Medicine at Tufts University School of Medicine. Her clinical interests include infections in immunocompromised patients and S. aureus infections, and her research focuses

Helen W. Boucher2020-03-02T14:31:43+00:00

Pamela Brown

Pamela Brown has over 30 years’ experience in anti-infective drug discovery gained within the biotech and pharmaceutical sectors. She is currently a consultant in Antibacterial Drug Discovery and Medicinal Chemistry offering independent advice and expertise to small and medium-sized enterprises (SMEs), biotechs and academic institutions. Pam was Director, Medicinal Chemistry at Cantab Anti-infectives for five years following its inception in 2012. There, Pam led the medicinal chemistry team towards novel polymyxins, resulting in a commercial deal with Spero Therapeutics in

Pamela Brown2018-03-08T14:01:34+00:00

Karen Bush

Karen Bush is a PhD graduate in biochemistry from Indiana University (IU). She spent 36 years in pharmaceutical research before joining the IU faculty to continue her focus on antibiotic drug discovery and development, based on her research on antibiotic resistance mechanisms. Karen’s major research has been in the area of beta-lactamases, the enzymes primarily responsible for antibiotic resistance to penicillins and cephalosporins and she has been a leader in beta-lactamase characterization and nomenclature. Karen’s research group has studied the

Karen Bush2020-01-31T12:59:07+00:00

Vincent Cattoir

Vincent Cattoir is currently Professor of Clinical Microbiology at the University of Rennes 1, and Head of the Clinical Bacteriology department of the University Hospital of Rennes, France. Vincent is the Director of the Lab Enterococci, affiliated to the National Reference Center for Antimicrobial Resistance. He is also a senior scientist in the INSERM U1230 at the University of Rennes 1, currently focused on regulatory mechanisms involved in the pathogenicity and antimicrobial resistance in opportunistic bacterial species such as Enterococcus

Vincent Cattoir2020-03-02T14:22:22+00:00

Ryan Cirz

Ryan Cirz is an independent consultant. Previously, he was founder and vice President of Research at Achaogen. Achaogen focused on discovering, developing and commercializing innovative antibacterials to treat multi-drug resistant (MDR) Gram-negative infections. Here, he participated in and led the advancement of four home-grown antibacterial assets through investigational new drug applications. Three of those programs advanced into the clinic with two advancing past phase one studies and one through US approval in 2018. At Achaogen, he oversaw the early-stage (pre-investigational

Ryan Cirz2020-04-06T09:43:44+00:00

Anthony Coates

Anthony Coates is the Founder and Chief Scientific Officer of Helperby Therapeutics, a biopharmaceutical company dedicated to developing the next generation of lifesaving antibiotics. Anthony created the company in 2002 and together with colleague Yanmin Hu invented Antibiotic Resistance Breakers (ARBs), a new form of ‘antibiotic renewable’ technology. With existing antibiotic treatments rapidly becoming obsolete, Helperby’s unique antibiotic technology outsmarts highly resistant bacteria by combining ARBs with old antibiotics such as colistin, to create a new and sustainable commercially viable

Anthony Coates2018-10-03T12:00:24+00:00

Matthew Cooper

Matthew Cooper is co-founder, Director and Chief Executive Officer of Inflazome, which develops inflammasome inhibitors for chronic inflammatory diseases. Matt is also Co-Founder and Director of Defensin Therapeutics and Affiliate Professor at Trinity College Dublin. He holds a fractional Professorial Research Fellow appointment at the University of Queensland, where he is Professor of Chemical Biology at the Institute of Molecular Bioscience and, Affiliate Professor in the School of Chemistry and Molecular Biology. Matt obtained his PhD in 1995 in organic

Matthew Cooper2020-02-04T12:12:01+00:00

Mike Dawson

Mike Dawson is a consultant in antimicrobial research, who has spent the last 14 years working in the biotech sector. Mike also has over 20 years’ experience in the pharmaceutical industry gained at GSK. As Head of Biotransformation and Natural Product Chemistry he played leading roles in natural product based drug discovery and the application of biological processes to drug manufacturing. He left GSK in 2003 to set up Novacta Biosystems where, as Chief Scientific Officer (CEO), he led the

Mike Dawson2020-01-14T08:56:50+00:00

George L. Drusano

George Drusano is director of the Institute for Therapeutic Innovation at the University of Florida, whose mission is to improve the therapy for serious infectious diseases. After graduating magna cum laude from the honours programme at Boston College, George graduated cum laude from the University of Maryland School of Medicine in Baltimore. He completed his medical internship and residency at the University of Maryland Hospital, where he was also Chief Medical Resident and a Fellow in Medicines in Infectious Diseases.

George L. Drusano2020-01-31T13:25:01+00:00

Jacques Dumas

Jacques Dumas is a trained chemist with over 20 years’ experience in discovery to clinical proof-of-concept in infectious diseases and oncology. He has been Chief Scientific Officer (CSO) of Tetraphase Pharmaceuticals since July 2015, where he oversees non-clinical sciences and CMC (Chemistry, Manufacturing and Controls) activities to support the company’s product pipeline. Jacques became CSO at Idenix Pharmaceuticals in January 2014, then Vice President at Merck following Merck’s acquisition of Idenix. Between 2007 and 2014, Jacques held several positions at

Jacques Dumas2018-03-12T07:45:59+00:00

Barry I. Eisenstein

Barry Eisenstein is the chair of the Scientific and Business Advisory Board of CARB-X, a public-private partnership based at Boston University, devoted to new antimicrobial drug and diagnostic development. Barry received his medical degree from Columbia University and subsequently trained in internal medicine and infectious diseases at the University of North Carolina. He has spent his career in academy and industry, serving as Chief of the Infectious Diseases division at the University of Texas Health Science Center, San Antonio then

Barry I. Eisenstein2020-01-31T13:25:36+00:00

Alice Erwin

Alice Erwin is an independent scientific consultant, providing advice on antibiotic discovery to academic and industrial research groups. She also conducts due-diligence evaluation of antibacterial programmes being evaluated as in-licensing or investing opportunities. Alice is an infectious disease microbiologist with experience in both academic and industrial settings. Her scientific research over the past thirty years has revolved around the structure and function of bacterial membranes, with particular interest in the contribution of lipopolysaccharides to both the pathogenesis and the intrinsic

Alice Erwin2020-01-31T13:07:03+00:00

Domingo Gargallo-Viola

Domingo Gargallo-Viola is a co-founder and Chief Scientific Officer at ABAC Therapeutics, a leader in pathogen-specific antibiotics that was formerly part of Grupo Ferrer Internacional based in Spain. Domingo has over 30 years’ experience in the discovery and development of anti-infective drugs. At ABAC Therapeutics he is focused on the discovery and development of first-in-class, novel mechanism of action, pathogen-specific, narrow spectrum antibiotics - for the treatment of severe and life-threatening infections due to multidrug-resistant organisms. He is also responsible

Domingo Gargallo-Viola2018-03-13T12:16:35+00:00

Olga Genilloud

Olga Genilloud, Scientific Director and Head of the Microbiology Department at Fundación MEDINA, has over 25 years’ extended research experience in the discovery and biosynthesis of novel natural products antibiotics, obtained in the academic, clinical environment and pharmaceutical sectors. Olga has a PhD in chemistry from the Complutense University of Madrid and has a solid background in industrial microbiology - with expertise in bacterial natural products, molecular biology, ecology and taxonomy, physiology, and production of secondary metabolites. Since 2009, Olga

Olga Genilloud2018-03-16T10:48:28+00:00

Mark J. Goldberger

Mark Goldberger is an independent consultant at Mark Goldberger MD MPH LLC Maryland, USA, where he advises pharmaceutical and biotech companies on the development of infectious diseases products. Before retiring in 2014 and becoming a consultant, Mark spent seven years at AbbVie - formerly part of Abbott - in various senior positons including vice president of regulatory affairs and senior advisor. In these roles he provided regulatory guidance and strategic advice with a focus on US Food and Drug Administration

Mark J. Goldberger2020-01-31T13:26:39+00:00

Trudy Grossman

Trudy Grossman is Vice President of Research at Azitra Inc., a company developing microbial-based therapies aimed at treating skin disorders. Previously she was Senior Director of Biology and Pharmacology at Melinta Therapeutics in New Haven, Connecticut, where she managed a team supporting antibiotic discovery and development. Trudy has worked in microbiology in increasing roles of seniority for over 25 years; most of that time applying the genetics, molecular biology, physiology, and biochemistry of bacteria to the discovery and development of

Trudy Grossman2020-02-04T12:20:46+00:00

Bob Hancock

Bob Hancock is a leading microbiologist in Canada, who has researched and taught at the University of British Columbia (UBC) for nearly 40 years. Bob is currently UBC Killam Professor of Microbiology and Immunology, an Associate Faculty Member at the Wellcome Trust Sanger Institute in the UK, and a Canada Research Chair in Health and Genomics. Bob is focused on designing new therapeutic strategies to treat infections - in the light of increasing antibiotic resistance and a dearth of new

Bob Hancock2018-03-12T13:58:07+00:00

Stephen Hawser

Stephen is Chief Executive Officer of IHMA Europe Sàrl based in Switzerland, a wholly owned affiliate of International Health Management Associates. Since it began operating in 2009, under Stephen’s leadership, IHMA has focused on providing a full suite of technical capabilities and domain expertise in all phases of antimicrobial drug development: drug discovery, clinical development, regulatory approval and commercialization. Before joining IHMA, Stephen held several key positions in the pharmaceutical industry spanning 15 years, focused on antibacterial and antifungal research

Stephen Hawser2018-03-26T08:12:05+00:00

Paul Heath

Paul Heath is a Professor and Honorary Consultant in Paediatric Infectious Diseases at St George's University Hospital’s NHS Foundation Trust and St George’s, University of London, where he co-leads the Paediatric Infectious Diseases Research Group and is the Director of the Vaccine Institute. Before joining St George’s, Paul was a research fellow in the Oxford Vaccine Group Department of Paediatrics, at John Radcliffe Hospital, Oxford. Paul’s research has focused on the epidemiology of vaccine-preventable diseases, and clinical vaccine trials, particularly

Paul Heath2018-10-03T12:13:42+00:00

William Hope

William Hope is the Dame Sally Davies Chair of AMR Research and Professor of Therapeutics and Infectious Diseases at the University of Liverpool where he also leads the Centre for Antimicrobial Pharmacodynamics (CAP). As part of the university’s Institute of Translational Medicine, this centre provides the pharmacodynamic packages for the development for new antimicrobial agents. William qualified in medicine in 1991, before undertaking specialist training in infectious diseases and clinical microbiology. He completed his PhD in antimicrobial pharmacology in 2006,

William Hope2020-01-31T12:34:18+00:00

Deborah Hung

Deborah Hung is is currently an associate professor in the Department of Molecular Biology at Massachusetts General Hospital and in the Department of Genetics at Harvard Medical School. She is Director of the Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, an infectious disease physician at Brigham and Women’s Hospital and Massachusetts General Hospital and is an attending critical care physician in the Medical Intensive Care Unit at Brigham and Women’s Hospital. Deborah works at the interface

Deborah Hung2020-03-02T12:46:06+00:00

Khalid Islam

Khalid Islam is the owner of Life Sciences Management GmbH, which consults with start-ups, emerging biotechs and pharma on drug discovery and development. He is also a founding partner of Sirius Healthcare Partners, an advisory boutique in the healthcare sector. Khalid is the Chairman of the Board of Directors of Fennec Pharma and Minoryx Therapeutics, a member of the Board of Directors of Immunomedics and an advisor to the Paris-based venture group Kurma Biofund. Khalid has over 30 years’ experience in

Khalid Islam2020-02-04T12:28:07+00:00

Nachum Kaplan

Nachum Kaplan is a co-founder of Nobelex Biotech and has been the Chief Scientific Officer (CSO) since its inception in 2014. Nachum leads on the discovery of new drugs, including overseeing antibacterial compound progression relative to milestone criteria and target product profiles. Nachum is also responsible for all in vitro microbiology studies, in vivo efficacy models and pharmacokinetic/pharmacodynamics (PK/PD) modelling. Before creating Nobelex, Nachum was CSO of Affinium Pharmaceuticals, a drug discovery and development company focused on novel antibiotic therapeutics.

Nachum Kaplan2018-03-08T15:05:49+00:00

Sushmita Lahiri

Sushmita Lahiri is Associate Director and a member of the External Innovation, Research Beyond Borders team at Boehringer Ingelheim. This group is the company’s radar for the next wave of innovation and is responsible for identifying emerging science and technologies in Gene therapy, Regenerative medicine, Microbiomes and Infectious diseases. Sushmita is responsible for establishing and leading research collaborations in infectious diseases in partnership with academia and small biotech companies. Prior to this role, Sushmita was Executive Director of Biology at

Sushmita Lahiri2019-08-16T09:44:49+00:00

Jennifer Leeds

Jennifer Leeds is Executive Director and Head of West Coast Search and Evaluation, Business Development and Licensing, for the Novartis Institutes for Biomedical Research (NIBR). She is responsible for identifying new science and technology from the western United States for potential partnering with Novartis. Before assuming her current role, Jennifer Leeds was Head of Antibacterial Discovery in the infectious diseases area of NIBR. She was responsible for the strategy and execution of the new antibacterial portfolio from target discovery through

Jennifer Leeds2020-02-04T12:35:10+00:00

David Lewis

David Lewis is currently the Director of Western Sydney Sexual Health Centre and conjoint Professor at the University of Sydney, Australia. Throughout his career, David has had a special interest in the clinical, microbiological and public health aspects of sexually transmitted infections (STIs) and HIV. David graduated as a medical doctor from the London Hospital Medical College, London University in 1987. Following senior house officer positions in general medicine, haematological oncology, infectious diseases, genitourinary and HIV medicine, David underwent specialist

David Lewis2020-01-10T15:10:27+00:00

Jian Li

Jian Li is Head of the Antimicrobial Systems Pharmacology Laboratory at the Biomedicine Discovery Institute, Monash University in Melbourne, Australia. He has also been a Web of Science Highly Cited Researcher in Pharmacology and Toxicology (2015-2017). Jian has an internationally leading track record in the pharmacology of polymyxins and the discovery of new antibiotics against Gram-negative ‘superbugs’. The majority of modern polymyxin pharmacology data were reported by his research group and he is the Editor-in-Chief of the first-ever book on

Jian Li2020-03-02T14:24:49+00:00

Sergio Lociuro

Sergio Lociuro is Chief Scientific Officer (CSO) at BioVersys AG where he leads the research and development of novel chemical entities that, upon binding to bacterial transcription regulators, are able to control/inhibit expression of resistance to given antibiotic classes, biofilm formation and virulence factors. Sergio has over 30 years’ experience in applied sciences and drug discovery gained in academia and pharma. He has held several positions in small and large pharmaceutical companies, such as a scientific coordinator at MMD (Lepetit),

Sergio Lociuro2018-03-09T13:10:50+00:00

Alexander Mankin

Alexander Mankin is Distinguished Professor and Director of the Center for Biomolecular Sciences at the University of Illinois at Chicago (UIC), USA. He also holds the title of A. Neyfakh Collegiate Professor at the College of Pharmacy, UIC. Alexander’s research focuses on the mechanisms of action of ribosomal antibiotics. Through research carried out by his laboratory and collaborations with pharmaceutical companies, he has helped identify the sites and modes of action of several important classes of antibacterials, including oxazolidinones, ketolides,

Alexander Mankin2018-10-03T14:13:30+00:00

Jeanne Marrazzo

Jeanne Marrazzo is Professor of Medicine and Director of the Division of Infectious Diseases at the University of Alabama, Birmingham, USA. She is internationally recognized for her research and education efforts in the field of sexually transmitted infections (STIs), especially as they affect women’s health. She is a fellow of the American College of Physicians and of the Infectious Diseases Society of America. She is board certified in infectious diseases. Jeanne conducts research on the human microbiome, specifically as it

Jeanne Marrazzo2018-08-29T13:03:33+00:00

Alita Miller

Alita Miller is a Vice President of Biology at Entasis Therapeutics, a small biotech outside of Boston, USA, dedicated to the discovery and development of novel antibacterial agents to treat serious infections by resistant Gram-negative bacteria. At Entasis, Alita oversees both preclinical biology and developmental microbiology research. As a member of the senior leadership team, she is also involved in the strategic planning and execution of the company’s long-term research objectives. Alita has over 18 years’ experience in antibacterial research,

Alita Miller2020-02-04T12:45:12+00:00

Stefan Miller

Stefan Miller is a scientific consultant at Lysando AG and an independent consultant. He has significant experience as a chief scientific officer (CSO) and chief executive officer (CEO) in biotech companies and focuses on technology and product development including intellectual property strategy. Stefan co-founded Profos AG in 2000 and was its CSO until 2008. There he led the development of microbial diagnostics products and worked on bacteriophage endolysins as novel targeted antibacterials for Gram-positive bacteria. To overcome the limitations of

Stefan Miller2020-01-28T16:09:08+00:00

Alex O’Neill

Alex O’Neill is Associate Professor at the University of Leeds, UK, and heads a research group whose aim is to better understand and address the problems presented by antibiotic resistance in bacterial pathogens. Alex’s twenty-year academic career has involved two particular areas of focus. The first is concerned with elucidation of the molecular mechanisms by which bacteria resist the effects of antibiotics. The second – and the one of greatest relevance to REVIVE – involves the discovery and biological characterization

Alex O’Neill2018-10-11T09:01:22+00:00

Malcolm Page

Malcolm Page, PhD, studied Biochemistry in the U.K. and worked at the EMBL Heidelberg and the Biozentrum, Basel. He joined Roche in 1990, working on the discovery of β-lactamase inhibitors and anti-MRSA cephalosporins. He subsequently became responsible for exploratory projects in the Infectious Diseases therapeutic area and worked on the validation and screening of novel targets for antibiotics. Later, he led the Discovery Technologies group at Roche. In 2000 he joined Basilea Pharmaceutica as Head of Biology and has continued

Malcolm Page2018-03-08T08:47:30+00:00

Alastair Parkes

Alastair Parkes currently leads medicinal chemistry in antibacterial drug discovery programmes at Evotec, a drug discovery alliance and development partnership company. Evotec is focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Alastair has worked at the company since 2006, first in the internal research department on proprietary central nervous system drug discovery programmes, followed by three years in oncology and, in antibacterial research since January 2014. Over the

Alastair Parkes2018-08-29T13:42:15+00:00

Antonio Perez

Antonio (Toni) Perez is Chief Medical Officer (CMO) and chairman of advisory boards in several pharmaceutical and biotech companies. Toni has over 30 years of experience in the life science sector in research, drug development, registration and the launch of therapies in infectious diseases, oncology, the central nervous system, and gastrointestinal tract and others. Since September 2013, he has been the CMO at Combioxin/LASCCO, a private Swiss clinical stage biotech company that develops innovative agents for the treatment of serious

Antonio Perez2020-01-31T13:08:54+00:00

David Pompliano

David Pompliano is a drug discovery entrepreneur. Working with venture-capitalists and academicians, he focuses on creating scientifically precocious, game-changing new commercial enterprises based on cutting edge science and technology discovered in academia. David is an Operating Partner of Accelerator Life Science Partners.  With Accelerator LSP and Gates Foundation backing, David co-founded Lodo Therapeutics in 2015 with Professor Sean Brady (Rockefeller University), and served as its Chief Scientific Officer (CSO) until September 2018. Lodo Therapeutics is a New York City-based company focused on metagenomics-based discovery and synthetic biological manipulation of novel secondary metabolite biosynthetic pathways to produce new medicines.  David continues to

David Pompliano2020-01-13T14:45:53+00:00

Michael Pucci

Michael Pucci is Executive Director of Early Drug Discovery at Spero Therapeutics in Cambridge, Massachusetts. In addition to providing input into current R&D programmes, he explores potential new anti-infective programmes for the company pipeline and gathers competitive intelligence in the field. He also oversees non-dilutive funding opportunities and assists in the preparation of grant and contract applications. Michael has nearly 30 years’ experience in antibacterial drug discovery and development. Before co-founding Spero in 2014 he was the Executive Director of

Michael Pucci2018-03-09T13:33:51+00:00

Daniel Ritz

Daniel Ritz has been the Director and Senior Group Leader in the biology department of drug discovery at Idorsia Pharmaceuticals since it was created in June 2017. There he is responsible for preclinical antibacterial projects focusing on Gram-negative and broad-spectrum compounds. Daniel’s background is in biochemistry and bacterial genetics where he has focused on early discovery and lead optimization of antibacterial compounds, preclinical development, and microbiology aspects during later development stages. He spent 12 years at Actelion Pharmaceuticals, before the

Daniel Ritz2018-10-03T13:08:48+00:00

Hans-Georg Sahl

Hans-Georg Sahl is Emeritus Professor at the University of Bonn. He has held various roles at the university since 1980 including research assistant, Assistant Professor for Medical Microbiology and was Professor of Medical and Pharmaceutical Microbiology until 2017. Hans-Georg has authored over 200 papers, mostly on the mechanisms of action of new antibiotic compounds. He is a named inventor on three patents. Hans-Georg studied biology and chemistry and earned a PhD in microbiology from the University of Bonn. He has

Hans-Georg Sahl2018-03-09T13:38:58+00:00

Sameeh M. Salama

Sameeh M Salama is the Vice President (VP) of Business Development at Fedora Pharmaceuticals, VP of Business Development at the management and business consultancy firm, Brass Dome Ventures, and was formerly VP of NAEJA Pharmaceuticals. Since his move to industry in 1994, he has been heavily involved in antibacterial and antifungal research. His most recent research involved the initial discovery of a series of potent β-lactamase inhibitors which were later licensed to Roche and are now in clinical development. Sameeh

Sameeh M. Salama2020-01-31T13:28:27+00:00

Stephen Senn

Stephen Senn is an independent consultant statistician with over 40 years’ experience. Stephen began his career in the National Health Service in England and as a lecturer in Scotland before joining the Swiss pharmaceutical industry in 1987. Since then his interests have been in statistical methods applied to drug development. He has held professorial posts at University College London and The University of Glasgow and most recently was head of the Competence Center for Methodology and Statistics at the Luxembourg

Stephen Senn2020-01-15T15:54:22+00:00

William Shafer

William (Bill) Shafer is Professor of Microbiology and Immunology at Emory University School of Medicine. He is a senior research career scientist at the Atlanta Veterans Affairs Medical Center, Director of the Antimicrobial Resistance and Therapeutic Discovery Training Program and Co-Director of the Emory Antibiotic Resistance Center. Bill has been on the faculty of Emory University since 1982, and continuously funded by the National Institutes of Health and the Department of Veterans Affairs since 1984 for his work on antibiotic

William Shafer2018-03-12T14:49:43+00:00

Karen J. Shaw

Karen Joy Shaw is President of Hearts Consulting Group, providing consulting services for antibacterial and antifungal drug discovery and development programs. Most recently she was Chief Scientific Officer at Amplyx Pharmaceuticals, where she was responsible for the preclinical development of fosmanogepix, a first-in-class broad spectrum agent currently in Phase 2 clinical trials for the treatment of invasive fungal infections. With her team at Amplyx, she discovered APX2039, which inhibits the same Gwt1 protein target, but demonstrates remarkable in vitro and

Karen J. Shaw2020-01-31T13:30:40+00:00

David Shlaes

David Shlaes, author of Antibiotics, The Perfect Storm (Springer) and The Drug Makers (Lulu), has had a 30-year career in anti-infectives spanning academia and industry - with a long-standing scientific interest in antimicrobial resistance. David graduated with a PhD and MD from Case Western Reserve University (CWRU) in Cleveland and after completing his post-graduate training in 1980, joined the faculty of CWRU in the Division of Infectious Diseases. He then taught and maintained an active research programme, cared for patients

David Shlaes2018-03-09T14:32:01+00:00

Lynn L. Silver

Lynn Silver is the owner of the independent consultancy LL Silver Consulting, where she advises the pharmaceutical industry on antibacterial discovery and preclinical development. Lynn is an expert in antibacterial agents, screen design and execution, microbiological evaluation of hits and leads, and studies of mechanism of action and resistance. Lynn set up her consultancy business in 2004, after taking early retirement following 21 years at Merck Research Laboratories. There she held various roles in research and supervised groups in the

Lynn L. Silver2020-01-31T13:30:28+00:00